The final 2025 KDIGO Guidelinesuggests treatment with Nefecon should be considered in the majority of patients at risk of progressive loss of kidney function
Asahi Kasei, a global provider of healthcare and pharmaceutical solutions, announced that Nefecon (marketed in the United States as TARPEYO (budesonide) delayed release capsules), has been included in the Kidney Disease: Improving Global Outcomes (KDIGO) 2025 Clinical Practice Guideline for the Management of IgA Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).
Health Technology Insights: Digital Initiative Strengthens Access to Mental Health Support
TARPEYO is a key product in Asahi Kasei’s pharmaceutical business, which the company has identified as a strategic growth area in its medium-term management plan. The inclusion of Nefecon in the KDIGO guidelines underscores its place in therapy and is expected to further support sustainable, long-term growth within Asahi Kasei’s healthcare portfolio.
The updated KDIGO 2025 guideline aims to standardize care and improve outcomes by providing evidence-based recommendations related to IgAN diagnosis, prognosis and treatment. It is considered the global standard for nephrology practice and plays a central role in shaping treatment decisions for patients with IgAN.
Health Technology Insights: Inovalon Launches New Tools to Enhance Connected Healthcare
The KDIGO 2025 guideline suggests treatment with a 9-month course of Nefecon for patients at risk of progressive loss of kidney function, recognizing the treatment benefit of Nefecon in reducing the loss of kidney function and reducing proteinuria as demonstrated in the NefIgArd phase 3 randomized placebo-controlled trial. The effect of Nefecon on proteinuria and kidney function was assessed in adults with biopsy-proven IgAN who were on a stable dose of maximally tolerated RAS inhibitor therapy. Adverse events were mild or moderate and generally resolved after treatment cessation. KDIGO also notes that Nefecon is the only treatment approved for IgAN to date that has been proven to reduce the levels of pathogenic forms of IgA, which is an underlying cause of the disease.
“The inclusion of Nefecon in the KDIGO 2025 Guideline provides important external validation of its place in therapy. It also reinforces its role as the first and only approved therapy for IgAN shown to reduce the levels of pathogenic IgA and as an essential part of the comprehensive treatment approach now suggested by KDIGO,” said Ken Shinomiya, Leader of the Healthcare sector of Asahi Kasei.
Health Technology Insights: Ambetter Health Kicks Off Marketplace Open Enrollment
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
Source- businesswire
